Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update

Yun Fan Liaw, Jia Horng Kao, Teerha Piratvisuth, Henry Lik Yuen Chan, Rong Nan Chien, Chun Jen Liu, Ed Gane, Stephen Locarnini, Seng Gee Lim, Kwang Hyub Han, Deepak Amarapurkar, Graham Cooksley, Wasim Jafri, Rosmawati Mohamed, Jin Lin Hou, Wan Long Chuang, Laurentius A. Lesmana, Jose D. Sollano, Dong Jin Suh, Masao Omata

Research output: Contribution to journalArticle

676 Citations (Scopus)

Abstract

Large volume of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2008. These include further studies in asymptomatic subjects with chronic HBV infection and community-based cohorts, the role of HBV genotype/naturally occurring HBV mutations, the application of non-invasive assessment of hepatic fibrosis and quantitation of HBV surface antigen and new drug or new strategies towards more effective therapy. To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings was discussed and debated. The earlier "Asian-Pacific consensus statement on the management of chronic hepatitis B" was revised accordingly. The key terms used in the statement were also defined. The new guidelines include general management, indications for fibrosis assessment, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patients receiving immune suppression or chemotherapy and patients in the setting of liver transplantation and hepatocellular carcinoma, are also included.

Original languageEnglish
Pages (from-to)531-561
Number of pages31
JournalHepatology International
Volume6
Issue number3
DOIs
Publication statusPublished - 2012 Jun

Fingerprint

Chronic Hepatitis B
Hepatitis B virus
Virus Diseases
Drug Therapy
Fibrosis
Viral Drug Resistance
Guidelines
Liver
Therapeutics
Hepatitis B Surface Antigens
Natural History
Pharmaceutical Preparations
Liver Transplantation
Hepatocellular Carcinoma
Genotype
Mutation

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Liaw, Y. F., Kao, J. H., Piratvisuth, T., Chan, H. L. Y., Chien, R. N., Liu, C. J., ... Omata, M. (2012). Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatology International, 6(3), 531-561. https://doi.org/10.1007/s12072-012-9365-4
Liaw, Yun Fan ; Kao, Jia Horng ; Piratvisuth, Teerha ; Chan, Henry Lik Yuen ; Chien, Rong Nan ; Liu, Chun Jen ; Gane, Ed ; Locarnini, Stephen ; Lim, Seng Gee ; Han, Kwang Hyub ; Amarapurkar, Deepak ; Cooksley, Graham ; Jafri, Wasim ; Mohamed, Rosmawati ; Hou, Jin Lin ; Chuang, Wan Long ; Lesmana, Laurentius A. ; Sollano, Jose D. ; Suh, Dong Jin ; Omata, Masao. / Asian-Pacific consensus statement on the management of chronic hepatitis B : A 2012 update. In: Hepatology International. 2012 ; Vol. 6, No. 3. pp. 531-561.
@article{0749d0df22ce487e87daa176b38fe69c,
title = "Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update",
abstract = "Large volume of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2008. These include further studies in asymptomatic subjects with chronic HBV infection and community-based cohorts, the role of HBV genotype/naturally occurring HBV mutations, the application of non-invasive assessment of hepatic fibrosis and quantitation of HBV surface antigen and new drug or new strategies towards more effective therapy. To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings was discussed and debated. The earlier {"}Asian-Pacific consensus statement on the management of chronic hepatitis B{"} was revised accordingly. The key terms used in the statement were also defined. The new guidelines include general management, indications for fibrosis assessment, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patients receiving immune suppression or chemotherapy and patients in the setting of liver transplantation and hepatocellular carcinoma, are also included.",
author = "Liaw, {Yun Fan} and Kao, {Jia Horng} and Teerha Piratvisuth and Chan, {Henry Lik Yuen} and Chien, {Rong Nan} and Liu, {Chun Jen} and Ed Gane and Stephen Locarnini and Lim, {Seng Gee} and Han, {Kwang Hyub} and Deepak Amarapurkar and Graham Cooksley and Wasim Jafri and Rosmawati Mohamed and Hou, {Jin Lin} and Chuang, {Wan Long} and Lesmana, {Laurentius A.} and Sollano, {Jose D.} and Suh, {Dong Jin} and Masao Omata",
year = "2012",
month = "6",
doi = "10.1007/s12072-012-9365-4",
language = "English",
volume = "6",
pages = "531--561",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",
number = "3",

}

Liaw, YF, Kao, JH, Piratvisuth, T, Chan, HLY, Chien, RN, Liu, CJ, Gane, E, Locarnini, S, Lim, SG, Han, KH, Amarapurkar, D, Cooksley, G, Jafri, W, Mohamed, R, Hou, JL, Chuang, WL, Lesmana, LA, Sollano, JD, Suh, DJ & Omata, M 2012, 'Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update', Hepatology International, vol. 6, no. 3, pp. 531-561. https://doi.org/10.1007/s12072-012-9365-4

Asian-Pacific consensus statement on the management of chronic hepatitis B : A 2012 update. / Liaw, Yun Fan; Kao, Jia Horng; Piratvisuth, Teerha; Chan, Henry Lik Yuen; Chien, Rong Nan; Liu, Chun Jen; Gane, Ed; Locarnini, Stephen; Lim, Seng Gee; Han, Kwang Hyub; Amarapurkar, Deepak; Cooksley, Graham; Jafri, Wasim; Mohamed, Rosmawati; Hou, Jin Lin; Chuang, Wan Long; Lesmana, Laurentius A.; Sollano, Jose D.; Suh, Dong Jin; Omata, Masao.

In: Hepatology International, Vol. 6, No. 3, 06.2012, p. 531-561.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Asian-Pacific consensus statement on the management of chronic hepatitis B

T2 - A 2012 update

AU - Liaw, Yun Fan

AU - Kao, Jia Horng

AU - Piratvisuth, Teerha

AU - Chan, Henry Lik Yuen

AU - Chien, Rong Nan

AU - Liu, Chun Jen

AU - Gane, Ed

AU - Locarnini, Stephen

AU - Lim, Seng Gee

AU - Han, Kwang Hyub

AU - Amarapurkar, Deepak

AU - Cooksley, Graham

AU - Jafri, Wasim

AU - Mohamed, Rosmawati

AU - Hou, Jin Lin

AU - Chuang, Wan Long

AU - Lesmana, Laurentius A.

AU - Sollano, Jose D.

AU - Suh, Dong Jin

AU - Omata, Masao

PY - 2012/6

Y1 - 2012/6

N2 - Large volume of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2008. These include further studies in asymptomatic subjects with chronic HBV infection and community-based cohorts, the role of HBV genotype/naturally occurring HBV mutations, the application of non-invasive assessment of hepatic fibrosis and quantitation of HBV surface antigen and new drug or new strategies towards more effective therapy. To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings was discussed and debated. The earlier "Asian-Pacific consensus statement on the management of chronic hepatitis B" was revised accordingly. The key terms used in the statement were also defined. The new guidelines include general management, indications for fibrosis assessment, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patients receiving immune suppression or chemotherapy and patients in the setting of liver transplantation and hepatocellular carcinoma, are also included.

AB - Large volume of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2008. These include further studies in asymptomatic subjects with chronic HBV infection and community-based cohorts, the role of HBV genotype/naturally occurring HBV mutations, the application of non-invasive assessment of hepatic fibrosis and quantitation of HBV surface antigen and new drug or new strategies towards more effective therapy. To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings was discussed and debated. The earlier "Asian-Pacific consensus statement on the management of chronic hepatitis B" was revised accordingly. The key terms used in the statement were also defined. The new guidelines include general management, indications for fibrosis assessment, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patients receiving immune suppression or chemotherapy and patients in the setting of liver transplantation and hepatocellular carcinoma, are also included.

UR - http://www.scopus.com/inward/record.url?scp=84865376141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865376141&partnerID=8YFLogxK

U2 - 10.1007/s12072-012-9365-4

DO - 10.1007/s12072-012-9365-4

M3 - Article

AN - SCOPUS:84865376141

VL - 6

SP - 531

EP - 561

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

IS - 3

ER -